Department of Dermatology, Beijing Friendship Hospital, the Capital Medical University, Beijing, China.
Department of Dermatology, Beijing Friendship Hospital, the Capital Medical University, Beijing, China.
Photodiagnosis Photodyn Ther. 2019 Mar;25:23-28. doi: 10.1016/j.pdpdt.2018.11.005. Epub 2018 Nov 6.
Daylight photodynamic therapy (dPDT) is suggested to be effective for actinic keratosis (AK). We performed a meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of dPDT versus conventional photodynamic therapy (cPDT) in patients with AK. Relevant studies were identified through a systematic search of PubMed, Embase, and the Cochrane Library. A fixed or random effect model was applied, depending on the heterogeneity. Six RCTs with 369 patients with 5,556 AK lesions that were undergoing dPDT or cPDT with red light and methyl aminolevulinate (MAL) were included. Overall, the incidence of complete response (CR) was not significantly different between the two groups (risk ratio [RR]: 0.93, p = 0.07). Subgroup analyses indicated that dPDT was non-inferior to cPDT for CR in studies only included grade III AK lesions (RR: 0.97, p = 0.41), but less effective for CR in studies which also included grade III lesions (RR = 0.87, p < 0.001). Subsequent meta-analyses showed that dPDT was associated with a significantly reduced maximal pain score (mean difference = -4.51, p < 0.001) and a lower risk of adverse events (RR = 0.70, p < 0.001) as compared with cPDT. These results suggested although dPDT was better tolerated, the treatment efficacy of dPDT is non-inferior to cPDT with red light and MAL only in grade III AK lesions. The relative therapeutic efficacy of dPDT in AK of grade III lesions in comparison with cPDT should be further evaluated.
日光光动力疗法(dPDT)被认为对光化性角化病(AK)有效。我们对随机对照试验(RCT)进行了荟萃分析,以比较 AK 患者接受 dPDT 与常规光动力疗法(cPDT)的疗效和安全性。通过系统检索 PubMed、Embase 和 Cochrane Library 确定了相关研究。根据异质性,应用固定或随机效应模型。纳入了 6 项 RCT,共 369 名患者,5556 处 AK 病变接受了 dPDT 或 cPDT,使用红光和甲基氨基酮戊酸(MAL)。总体而言,两组完全缓解(CR)的发生率无显著差异(风险比 [RR]:0.93,p=0.07)。亚组分析表明,dPDT 在仅包括 III 级 AK 病变的研究中对 CR 不劣于 cPDT(RR:0.97,p=0.41),但在也包括 III 级病变的研究中对 CR 效果较差(RR=0.87,p<0.001)。随后的荟萃分析表明,与 cPDT 相比,dPDT 与明显降低的最大疼痛评分(平均差异=-4.51,p<0.001)和不良反应风险降低相关(RR=0.70,p<0.001)。这些结果表明,尽管 dPDT 耐受性更好,但 dPDT 联合红光和 MAL 治疗 III 级 AK 病变的疗效与 cPDT 相当。应进一步评估 dPDT 在 III 级 AK 病变中的相对治疗效果与 cPDT 相比。